Market Research Report
Malaysia Pharmaceuticals & Healthcare Q3 2019
|Published by||Fitch Solutions, Inc.||Product code||179529|
|Published||Content info||71 Pages
Delivery time: 1-2 business days
|Malaysia Pharmaceuticals & Healthcare Q3 2019|
|Published: June 4, 2019||Content info: 71 Pages||
Innovative pharmaceutical firms will be faced with myriad challenges in Malaysia, ranging from weak intellectual property enforcement to preferential treatment of local manufacturers. Additionally, while the government has adopted a policy which prioritises the welfare of Malaysians, the use of a non-transparent process to issue compulsory licences will continue to undermine investment by innovative drugmakers in the country. As such, Malaysia will remain a highly unattractive market for patented drug launches. Nonetheless, the government's growing investment in healthcare and a rising chronic disease burden will support the growth of the Malaysian pharmaceutical market over the long term.